## Creatinine drug-biomaker interactions
Modeling of clinical creatinine drug-biomarker interaction studies with trimethoprim, pyrimethamine and cimetidine for model evaluation

### Repository files
Within this repository, we distribute MoBi project files containing simulations of clinical studies used to evaluate the predictive performance of the creatinine model regarding the trimethoprim-creatinine, pyrimethamine-creatinine and cimetidine-creatinine drug-biomarker interactions, including the respective observed data [[1](#reference)][[2](#reference)][[3](#reference)]. The applied [trimethoprim](https://github.com/Open-Systems-Pharmacology/Trimethoprim-Model) [[4](#reference)], [cimetidine](https://github.com/Open-Systems-Pharmacology/Cimetidine-Model) [[5](#reference)] and pyrimethamine models have been published previously, the latter refined to apply it for transporter-mediated interactions [[6](#reference)]. For further details and documentation, please refer to [[7](#reference)].

### Version information
MoBi Version 9.1

### Code of conduct
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology [code of conduct](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODE_OF_CONDUCT.md#contributor-covenant-code-of-conduct).

### Contribution
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the [contribution guidelines](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CONTRIBUTING.md#ways-to-contribute). If you are contributing code, please be familiar with the [coding standard](https://github.com/Open-Systems-Pharmacology/Suite/blob/master/CODING_STANDARDS.md#visual-studio-settings).

### License
The model code is distributed under the [GPLv2 License](https://github.com/Open-Systems-Pharmacology/Suite/blob/develop/LICENSE).

### Reference
[[1] Shouval D, Ligumsky M, Ben-Ishay D. Effect of co-trimoxazole on normal creatinine clearance. The Lancet. 1978;1(8058):244-5.](https://www.sciencedirect.com/science/article/pii/S0140673678904865?via%3Dihub)

[[2] Miyake T, Kimoto E, Luo L, Mathialagan S, Horlbogen LM, Ramanathan R, Wood LS, Johnson JG, Le VH, Vourvahis M, Rodrigues AD, Muto C, Furihata K, Sugiyama Y, Kusuhara H. Identification of appropriate endogenous biomarker for risk assessment of multidrug and toxin extrusion protein-mediated drug-drug interactions in healthy volunteers. Clinical Pharmacology & Therapeutics. 2021;109(2):507-6.](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2022)

[[3] Serdar MA, Kurt I, Ozcelik F, Urhan M, Ilgan S, Yenicesu M, Kenar L, Kutluay T. A practical approach to glomerular filtration rate measurements: creatinine clearance estimation using cimetidine. Annals of Clinical & Laboratory Science. 2001;31(3):265-73.](http://www.annclinlabsci.org/content/31/3/265.long)

[[4] Türk D, Hanke N, Lehr T. A physiologically-based pharmacokinetic model of trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 drug-drug-gene interaction predictions. Pharmaceutics. 2020;12(11):1074.](https://www.mdpi.com/1999-4923/12/11/1074)

[[5] Sjögren E, Tarning J, Barnes KI, Jonsson EN. A physiologically-based pharmacokinetic framework for prediction of drug exposure in malnourished children. Pharmaceutics. 2021;13(2):204.](https://www.mdpi.com/1999-4923/13/2/204)

[[6] Hanke N, Türk D, Selzer D, Ishiguro N, Ebner T, Wiebe S, Müller F, Stopfer P, Nock V, Lehr T. A Comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. Clinical Pharmacokinetics. 2020;59(11):1419-31.](https://link.springer.com/article/10.1007/s40262-020-00896-w)

[[7] Türk D, Müller F, Fromm MF, Selzer D, Dallmann R, Lehr T. Renal transporter-mediated drug-biomarker interactions of the endogenous substrates creatinine and N1 -methylnicotinamide: a PBPK modeling approach. Clinical Pharmacology & Therapeutics. 2022. Online ahead of print](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2636)
